['hodgkin disease']
['brentuximab vedotin']

        Inclusion Criteria:

          1. Histologically confirmed CD30 positive classical Hodgkin lymphoma

          2. No previous treatment for classical Hodgkin lymphoma

          3. Aged ≥ 16 years

          4. Stages II (with B symptoms, extranodal disease, bulky disease, ≥3 sites of nodal
             involvement, fewer than 3 sites of nodal involvement but unsuitable for radiotherapy
             because of anatomical distribution or ESR ≥50 mm/h), III and IV classical Hodgkin
             lymphoma

          5. Any of the following:

             At any age and with ECOG score of 0, 1, 2 or 3, for whom standard chemotherapy
             considered inappropriate because:

               -  Impaired cardiac function defined either by an ejection fraction of < 50%
                  assessed by echocardiogram or nuclear medicine scan (MUGA)

               -  Left ventricular ejection fraction ≥50% measured by echocardiography or MUGA but
                  in the presence of significant co-morbidities or cardiac risk factors such as
                  diabetes mellitus, hypertension, peripheral vascular disease, ischaemic heart
                  disease, previous myocardial infarction, obesity, stroke or transient ischaemic
                  attacks (TIA) that make anthracycline-containing chemotherapy inadvisable as
                  determined by the investigator.

               -  Heart failure clinically determined by the presence of New York Heart Association
                  (NYHA) heart failure grade II and III due to a cause other than Hodgkin Lymphoma

               -  Impaired respiratory function with DLCO and/or FVC/FEV1 ratio <75% of predicted
                  due to a cause other than Hodgkin lymphoma

             For patients aged 60 years or older,

               -  an ECOG score of 1, 2 or 3 for any reason, before the start of permitted steroids
                  (see section 7.9) and considered unsuitable for treatment with standard
                  chemotherapy by the investigator

             All co-morbidities must be documented on the baseline form and the CIRS-G score (if 60
             years or older) recorded.

          6. FDG avid disease - proven by PET scan

          7. Measurable disease with at least one lesion measuring >1.5 cm in long axis diameter
             (for nodal lesions) or >1.0cm in long axis diameter (for extra-nodal lesions)

          8. Written informed consent

          9. Able to comply with requirements of the protocol (including PET scans)

         10. Agree and be able to use adequate contraception if required

        Exclusion Criteria:

          1. Nodular lymphocyte predominant Hodgkin lymphoma

          2. Grade 2 or worse peripheral neuropathy

          3. Haemoglobin <90 g/L (transfusion allowed)

          4. Unsupported neutrophil count <1.0 x 109/l and platelet count <100 x 109/l unless due
             to bone marrow infiltration by Hodgkin lymphoma demonstrated by trephine biopsy

          5. Serum bilirubin ≥1.5 times upper limit normal unless due to Hodgkin lymphoma or
             Gilbert's syndrome

          6. Creatinine clearance <30 ml/min (calculated by the modified Cockroft-Gault formula,
             see appendix) unless due to Hodgkin lymphoma. Patients with an eGFR <30 ml/min but a
             measured GFR by another method (e.g. EDTA) of 30ml/min or greater would be eligible.

          7. Pregnant or lactating women

          8. Any other cancer diagnosis within the last 24 months - except for:

               -  Appropriately treated superficial melanoma, basal cell carcinoma and squamous
                  cell carcinoma of the skin

               -  Appropriately treated cervical intra-epithelial neoplasia

               -  In situ or organ confined prostate cancer not currently requiring therapy

             Previous cancers treated with curative intent and with no evidence of recurrence
             following a minimum of at least 2 years of follow-up are permitted.

          9. The use of other investigational or anti-neoplastic agents within the previous 6 weeks
             or during the trial.

         10. Known to be HIV, Hep B positive (Hep B Core antibody positive allows inclusion
             providing surface / core antigen both negative) or Hep C positive (Hep C antibody
             positive allows inclusion providing PCR for viral RNA is negative).

         11. Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient
             contained in the drug formulation of brentuximab vedotin.

         12. Known cerebral or meningeal involvement by Hodgkin lymphoma

         13. Symptoms or signs of progressive multifocal leukoencephalopathy (PML)

         14. Any active systemic viral, bacterial, or fungal infection requiring intravenous
             antimicrobials within 2 weeks prior to registration

         15. Evidence of current uncontrolled cardiovascular conditions, including unstable angina
             and NYHA grade IV heart failure

         16. ECOG 4 at registration
      